Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm, Cure Forward Partner on NGS-based Cancer Molecular Profiling

NEW YORK(GenomeWeb) – Paradigm and newly formed Cure Forward today announced an agreement under which Paradigm will provide next-generation sequencing-based molecular profiling for cancer patients. 

Paradigm will serve as a core diagnostic laboratory partner under the deal and will provide its PCDx clinical-grade NGS test to the collaboration, which is aimed at providing cancer patients better access to their molecular profiling data, the Ann Arbor, Michigan-based non-profit diagnostics firm said. Patients will be able to use their molecular data at Cure Forward to find relevant information, be invited to clinical trials, and participate in communities with similar patients, it added. 

PCDx interrogates relevant genomic targets at more than 5,000X average depth of coverage with 66 therapeutic associations, Paradigm said, adding test results can be delivered in four to five business days. 

Paradigm will report results to physicians ordering the test, and patients will be able to electronically retrieve the data through the Cure Forward platform. Based in Cambridge, Massachusetts, Cure Forward calls itself a "patient activation company" that provides patients the ability to use their molecular test data. 

At Cure Forward's website, set to launch in September, patients will be able to request their genomic test results from physician-ordered laboratory tests. It has established partnership with diagnostic labs for on-demand data access upon patient requests, the firm said in a separate announcement. Its initial focus will be on oncology with plans to provide offerings in other conditions such as neurology and cardiovascular disease later.

"Cure Forward will provide Paradigm with a unique opportunity and cutting-edge social platform to engage oncology patients directly," Paradigm CEO Robert Penny said in a statement. "Like Cure Forward, we believe that patients own their data, which they can utilize to more proactively improve their care and outcomes."

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.